Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00067
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
MDP26
|
|||||
| Structure |
|
|||||
| Sequence |
KKQLQLQLQLQLQLKK
|
|||||
| Peptide Type |
Linear
|
|||||
| PDC Transmembrane Types | Cell targeting peptides (CTPs) | |||||
| Formula |
C90H164N26O23
|
|||||
| Isosmiles |
[H]NCCCC[C@H](NC(=O)[C@H](CCCCN[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@H](CCCCN[H])NC(=O)[C@H](CCCCN[H])N[H])C(=O)O
|
|||||
| InChI |
InChI=1S/C90H164N26O23/c1-47(2)41-63(84(132)103-55(23-15-19-39-93)77(125)110-62(90(138)139)24-16-20-40-94)111-79(127)57(26-32-70(97)118)105-86(134)65(43-49(5)6)113-81(129)59(28-34-72(99)120)107-88(136)67(45-51(9)10)115-83(131)61(30-36-74(101)122)109-89(137)68(46-52(11)12)116-82(130)60(29-35-73(100)121)108-87(135)66(44-50(7)8)114-80(128)58(27-33-71(98)119)106-85(133)64(42-48(3)4)112-78(126)56(25-31-69(96)117)104-76(124)54(22-14-18-38-92)102-75(123)53(95)21-13-17-37-91/h47-68H,13-46,91-95H2,1-12H3,(H2,96,117)(H2,97,118)(H2,98,119)(H2,99,120)(H2,100,121)(H2,101,122)(H,102,123)(H,103,132)(H,104,124)(H,105,134)(H,106,133)(H,107,136)(H,108,135)(H,109,137)(H,110,125)(H,111,127)(H,112,126)(H,113,129)(H,114,128)(H,115,131)(H,116,130)(H,138,139)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-/m0/s1
|
|||||
| InChIKey |
CMYXPQBISVBRQG-MFMIKQJCSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1978.461
|
Polar area
|
862.44
|
||
|
Complexity
|
1977.246266
|
xlogp Value
|
-5.9441
|
|||
|
Heavy Count
|
139
|
Rot Bonds
|
82
|
|||
|
Hbond acc
|
27
|
Hbond Donor
|
27
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
HCPTMDP26-PEG [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.27 µM
|
|||
| Description |
Peptides and drug-peptide conjugates were incubated with HepG2 cells for 48 hours followed by a CCK8 cytotoxicity assay. Despite the large population of the positive charges, supramolecular peptides alone demonstrated negligible cytotoxicity (Fig. S8, ESI). The drug conjugate, HCPT-MDP26-PEG showed a dose-dependent cytotoxicity with an IC50of 1.27 uM, comparable to the IC50of free HCPT at ˜1.3 uM (Fig. 3a). At a high drug dosage, the drug conjugate is much more potent than free HCPT.
Click to Show/Hide
|
||||
| In Vitro Model | Hepatoblastoma | L-O2 cell line | CVCL_0027 | ||
References